FDA Approves Adcetris for Refractory Hodgkin’s Disease and a Rare T-Cell Lymphoma

Late Friday afternoon, the FDA announced its approval, upon accelerated review, of a new drug, Adcetris (brentuximab) for patients with Hodgkin’s lymphoma that has relapsed after bone marrow transplant and for some patients with T-cell anaplastic large cell lymphoma (ALCL). This interests me for a lot of reasons, among them that I used to work in the field of lymphoma immunology […]

Posted in cancer treatment, Communication, Medical News, Oncology (cancer)Tagged , , , , , , , , , , Leave a Comment on FDA Approves Adcetris for Refractory Hodgkin’s Disease and a Rare T-Cell Lymphoma

Some Articles I Authored A While Ago

This post, on my research in cancer immunology, is strangely personal. At one level, what follows is nothing more than a list, a narrative if you will, a sketch of a formative chunk of my career and personal history. I’ve wanted to put this out there (here) for quite a while, but couldn’t: It’s been […]

Posted in Academic Medicine, from the author, Life, Life as a DoctorTagged , , , , , , , , , , 2 Comments on Some Articles I Authored A While Ago

Looking Ahead: 7 Cancer Topics for the Future

Here’s my short list, culled from newsworthy developments that might improve health, reduce costs of care and better patients’ lives between now and 2020, starting this year: 1. “Real” Alternative Medicine. By this I don’t mean infinitely-diluted homeopathic solutions sold in fancy bottles at high prices, but real remedies extracted from nature and sometimes ancient […]

Posted in Future of Medicine, Health IT, Oncology (cancer), Science, Selected TopicsTagged , , , , , , , , , , , , Leave a Comment on Looking Ahead: 7 Cancer Topics for the Future
newsletter software